301 related articles for article (PubMed ID: 24160850)
1. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
Poiré X; Moser BK; Gallagher RE; Laumann K; Bloomfield CD; Powell BL; Koval G; Gulati K; Holowka N; Larson RA; Tallman MS; Appelbaum FR; Sher D; Willman C; Paietta E; Stock W
Leuk Lymphoma; 2014 Jul; 55(7):1523-32. PubMed ID: 24160850
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
[TBL] [Abstract][Full Text] [Related]
3. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
[TBL] [Abstract][Full Text] [Related]
4. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
Xu LW; Su YZ; Tao HF
Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
[TBL] [Abstract][Full Text] [Related]
5. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.
Mathews V; Thomas M; Srivastava VM; George B; Srivastava A; Chandy M
Haematologica; 2007 Jul; 92(7):994-5. PubMed ID: 17606455
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia.
Dillon R; Grimwade D
Leuk Lymphoma; 2014 Jul; 55(7):1444-6. PubMed ID: 24313832
[No Abstract] [Full Text] [Related]
7. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.
Yoo SJ; Park CJ; Jang S; Seo EJ; Lee KH; Chi HS
Leuk Lymphoma; 2006 Sep; 47(9):1788-93. PubMed ID: 17064989
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients.
Yaghmaie M; Alimoghaddam K; Mozdarani H; Ghavamzadeh A; Hajhashemi M; Aznab M; Ghaffari SH
Iran Biomed J; 2012; 16(1):10-7. PubMed ID: 22562027
[TBL] [Abstract][Full Text] [Related]
9. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
10. [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].
Xue MX; Qiu HY; Feng YF; Zhu ZL; Chang WR; Liang JY; Chen SN; Cen JN; Xue YQ; Liu YJ; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):757-61. PubMed ID: 19176014
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.
Barragán E; Montesinos P; Camos M; González M; Calasanz MJ; Román-Gómez J; Gómez-Casares MT; Ayala R; López J; Fuster Ó; Colomer D; Chillón C; Larrayoz MJ; Sánchez-Godoy P; González-Campos J; Manso F; Amador ML; Vellenga E; Lowenberg B; Sanz MA; ;
Haematologica; 2011 Oct; 96(10):1470-7. PubMed ID: 21685470
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113
[TBL] [Abstract][Full Text] [Related]
14. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
Gale RE; Hills R; Pizzey AR; Kottaridis PD; Swirsky D; Gilkes AF; Nugent E; Mills KI; Wheatley K; Solomon E; Burnett AK; Linch DC; Grimwade D;
Blood; 2005 Dec; 106(12):3768-76. PubMed ID: 16105978
[TBL] [Abstract][Full Text] [Related]
15. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
Chillón MC; Santamaría C; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Marín L; Caballero MD; Vidriales MB; Ramos F; Bernal T; Díaz-Mediavilla J; García de Coca A; Peñarrubia MJ; Queizán JA; Giraldo P; San Miguel JF; González M
Haematologica; 2010 May; 95(5):745-51. PubMed ID: 20133893
[TBL] [Abstract][Full Text] [Related]
16. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract][Full Text] [Related]
17. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
Shen Y; Fu YK; Zhu YM; Lou YJ; Gu ZH; Shi JY; Chen B; Chen C; Zhu HH; Hu J; Zhao WL; Mi JQ; Chen L; Zhu HM; Shen ZX; Jin J; Wang ZY; Li JM; Chen Z; Chen SJ
EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
Schnittger S; Bacher U; Haferlach C; Kern W; Alpermann T; Haferlach T
Haematologica; 2011 Dec; 96(12):1799-807. PubMed ID: 21859732
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
